SEC Form 4 · accession 0001477932-17-004615
Citius Pharmaceuticals, Inc. · CTXR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Myron Z Holubiak
Officer — President and CEO · Director
Period of report
Sep 15, 2017
Accepted (ET)
Sep 19, 2017 · 9:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001506251
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 516,967 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $3.45 | Sep 15, 2017 | A | 40,000 | A | — | Sep 13, 2027 | Common Stock | 40,000 | 40,000 | D |
| Options to Purchase Common StockF2 | $8.10 | holding | — | — | — | — | Oct 1, 2025 | Common Stock | 26,667 | 26,667 | D |
| Warrant to Purchase Common StockF3 | $6.21 | holding | — | — | — | — | Jun 12, 2019 | Common Stock | 19,615 | 19,615 | D |
Explanation of responses
- F1One-third of the shares of the Company's common stock (the "Common Stock") underlying the grant vest on the first anniversary of the vesting commencement date, September 13, 2018. The remaining shares of Common Stock underlying the grant vest in equal monthly installments at the end of each month for two years following the initial vest, provided the Reporting Person continues to serve as a member of the Company's Board of Directors as of each such vesting date.
- F2The option granted vested and became exercisable as follows: the option to purchase 2,667 shares of Common Stock vested on October 1, 2015, and the balance of the option to purchase shares of Common Stock vested in twelve (12) equal installments commencing on December 31, 2015. The option was issued pursuant to the Company's 2014 Stock Incentive Plan.
- F3The warrant is fully vested and exercisable immediately.
Remarks
All numbers reflect a 1-for-15 reverse stock split on June 9, 2017.